X-linked cardiomyopathies (DCM) are genetically inherited diseases, resulting from defects in the dystrophin gene. Dystrophin is a large rod-like protein linking intracellular actin with proteins of the extracellular matrix. The major clinical benefits deriving from the identification of dystrophin defects in patients with DCM include the molecular diagnosis of the disease in the proband, the early diagnosis of affected young relatives and female carrier detection.
X-linked DCM was first described by Berko et al. (1) in 1987 in one large kindred with 11 affected young men. Since then, nine more families have been reported (Table 1 ) (2) (3) (4) (5) (6) (7) (8) (9) (10) . When heart involvement is dominant and skeletal muscle impairment is minimal or null, these disorders are defined as X-linked DCM (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) , even if the muscle isoform of serum creatine phosphokinase muscle isoform (sCPK-MM) is increased and muscle biopsy shows dystrophic changes and decreased dystrophin immunostain (2-10) ( Table 2 ). At present, known gene defects associated with X-linked DCM seem to cluster in two different regions: 5Ј (the majority), including muscle promoter-exon 1 and hinge region defects (point mutations, deletions, inversions and transposable element insertions) (3, (5) (6) (7) (8) 10 ) and midrod domain exons (Becker-type mutations) ( [9, 11, 12] . X-linked DCMs with Becker type defects have been defined as Becker muscular dystrophy (BMD) with dominant cardiac involvement (11, 12) , especially before X-linked DCM was proposed as a distinct entity (2) .
Dystrophin defects presenting with isolated or predominant cardiac involvement may be clinically indistinguishable from idiopathic DCM, especially when peripheral myopathy is not overt or sCPK is normal or only mildly increased or if the family is small and masks an X-linked recessive inheritance. Dystrophin defects may be missed on conventional histopathologic study of endomyocardial biopsy (EMB), unless specifically investigated. Ultrastructural studies of EMB tissue, where hypercontraction band artifacts are the rule, do not allow recognition of typical delta lesions, which are the ultrastructural markers of dystrophin defects in skeletal muscle (13) and do not provide diagnostic information. Therefore, to identify dystrophin defects, all potentially affected patients should be screened with immunohistochemical and molecular methods. However, the number and size of EMB samples limit the spectrum of routine diagnostic procedures. Biopsy samples are too small for Western blot, and tissue diagnosis only relies on the interpretation of immunohistochemistry for the C-and N-terminal and for rod and midrod domains of dystrophin. Dystrophin gene analysis with multiplex polymerase chain To clinically assess the prevalence of dystrophin defects in a DCM male population and characterize the disease, we performed a prospective molecular and immunohistochemical screening in 201 consecutive men referred to our hospital for evaluation and management of DCM in the last four years.
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METHODS
From January 1995 to June 1999, 201 consecutive DCM men (ages 15 to 66 years; mean Ϯ SD ϭ 42.4 Ϯ 12.8) were evaluated at the IRCCS Policlinico San Matteo of Pavia, Italy. Dilated cardiomyopathy was diagnosed on the basis of World Health Organization (WHO) criteria (17) . Patients with specific heart muscle diseases, such as amyloidosis, hemochromatosis, glycogenosis, etc., patients with familial DCM with autosomal inheritance, as well as patients with prior proven diagnosis of dystrophin defects were excluded. Patients with suspected BMD, not proven with immunochemical or molecular studies, patients with a family history suggestive of an X-linked disease, and patients diagnosed with limb-girdle muscular dystrophy (LGMD) in other centers were not excluded. All patients entered a diagnostic protocol that consisted of clinical examination, biochemical investigation (total sCPK, sCPK cardiac isoform [MB] and lactic dehydrogenase), electrocardiography (ECG), chest-X-ray, two-dimensional and Doppler echocardiography, right and left heart catheterization, coronary angiography and right ventricular EMB. Informed and consenting relatives were screened for DCM with clinical examination, biochemical blood tests, ECG, signal averaged ECG and echocardiogram, and the disease was defined as familial or nonfamilial (18) .
Right ventricular endomyocardial biopsy. Biopsy was performed in all patients as per standard protocol (19) .
Biopsy samples were processed for light microscopy and ultrastructural study (19 -21) . One frozen sample was used for dystrophin immunostaining and one for molecular study (see following text).
All biopsy specimens from the 201 patients were evaluated with light and electron microscopy, and routine immunohistochemical studies were performed to diagnose or exclude myocarditis (19) . Screening for enteroviral RNA was undertaken with reverse transcriptase (RT)-PCR and nested RT-PCR as well (22) . Amyloid and iron deposits were excluded by Congo red and Pearls' stains as well as with ultrastructural study (23, 24) . Desmin accumulation was excluded by ultrastructural examination (20) . In addition, mitochondrial oxidative phosphorylation defects were analyzed with specific histoenzymatic stains (21, 25) .
Immunohistochemical study of dystrophin and dystrophin-associated proteins. Four monoclonal antibodies that recognize N-terminal, rod, midrod (exons 49 -51) and C-terminal domain epitopes of the dystrophin molecule (Novocastra Laboratories, Newcastle Upon Tyne, United Kingdom) were used to immunostain frozen myocardial sections. Dystrophin-associated glycoproteins (DAGs) were evaluated with monoclonal antibodies that recognize alpha, beta, gamma and delta sarcoglycan, beta dystroglycan, merosin and spectrin (Novocastra Laboratories, New Castle Upon Tyne, United Kingdom). Negative control studies were performed with the substitution of the primary antibodies either with normal swine serum or with unrelated primary antibody from the same species as the primary antibody. Immunohistochemical staining was performed with the avidin-biotin peroxidase complex (Amersham Life Science, Bucks, United Kingdom), using diaminobenzidine tetrahydrochloride as chromogen substrate or with fluorescein-conjugated secondary antibodies (Boehringer Mannheim, Germany) (19, 20) . DNA analysis. The DNA was isolated from peripheral blood leukocytes by standard methods (26) . In all DCM patients, analysis of the dystrophin gene was performed with different multiplex and single PCR assays; 100 ng of genomic DNA was amplified with Taq Gold Polymerase (Perkin Elmer-Applied Biosystems, Foster City, California) in 50 l reaction solution. The assays tested exons 1-muscle promoter, 3, 6, 13, 43, 47, 52 and 60 in one reaction, exons 49 and 50 in a second (14) ; exons 4, 8, 12, 17, 19, 44, 45, 48 and 51 in a third (15) and exons 16, 32, 34, 41, 42, 53 in a fourth reaction (16) . Two multiplex PCR assays were standardized for exons 7, 46, 66, 68, 70 and exons 29, 54, 58, 61, 69, and 76 at the following conditions: denaturation 10Ј at 95°C; denaturation 30Љ at 94°C, annealing 30Љ at 53°C, elongation 4Ј at 65°C for 23 cycles; final elongation 6Ј at 65°C. Exons 9 and 64 were amplified in single PCR reactions. Primers were designed according to the Leiden Muscular Dystrophy Pages. All deletions identified in multiplex PCR assays were confirmed using single exon PCR. The nucleotide sequence of exon 9 (10) was 
RESULTS
Of the 201 patients, 13 (6.5%) were diagnosed with dystrophin defects (Table 3 ). In 10 of the 13 cases, the molecular analysis identified the gene defects. Before admission, of these 13 patients, four (30.7%) were unsuspected, three (23.1%) had been misdiagnosed as limb-girdle myopathy and six (46.2%) were clinically suspected as BMD, mostly based on high sCPK levels, plus family history in two. Total sCPK levels were raised in 10 patients; sCPK MB levels were normal in all patients. Of the 188 patients with nondystrophin-related DCM, four patients had high sCPK levels: two were affected by non-X-linked familial DCM and two by nonfamilial DCM.
Stratification by age. The highest prevalence of dystrophin defects was observed in male patients younger than 20 years (Fig. 1) ; eight of the 35 men younger than 30 had dystrophin defects (22.8%). Seven of the eight patients had some clinical evidence of peripheral myopathy mostly based on increased total sCPK levels, suspected as BMD in six (two with family history) and misdiagnosed as LGMD in one; the diagnosis was unsuspected in one patient with normal sCPK values. Of five patients older than 30 years of age, two had a prior clinically misdiagnosis of LGMD and three were unsuspected (Table 3) .
Genotype-phenotype correlation. Gene defects were identified in 10 of the 13 patients and consisted of deletions of one or more than one exon of the dystrophin gene. In eight of 10, deletions exclusively affected regions spanning between exons 45 and 53 (Table 3) , while in two patients deletions affected exons coding for N-terminus of the protein.
In three patients the gene defect could not be identified and analysis is being continued. No patient had promoter defects or point mutations in exon 9. Clinical outcome was better for seven patients with exclusive rod domain defects: five are alive, all stable in New York Heart Association classes II and III, after a mean follow-up of 3.4 years (range from six months [the last diagnosed 50-year-old patient] to six years), one underwent transplantation four years after onset of cardiac symptoms and one died of congestive heart failure two years after the onset of symptoms while awaiting heart transplantation.
Two remaining patients with N-terminal defects, as well as those in whom molecular defects were not identified, had relatively poor outcomes; one died a year after onset of symptoms and four underwent heart transplantation with a mean interval of 1.9 years after onset (range 11 months to four years). All transplanted patients are alive 20, 13, 10, 10 and 3 months after surgery. Overall, the patients with nonrod domain defects had worse pathophysiological parameters at the time of their initial evaluation (Table 3) .
Familial disease. Family history was positive in four cases. In two of these patients, the diagnosis had been suspected based on affected male cousins. Relatives of two other families with no prior history of dystrophin defect accepted both clinical evaluation and molecular analysis. The extension of family studies to other patients was either refused or impossible. In one of the two families that accepted evaluation, the proband had a younger brother and sister; both were shown to be respectively not affected and noncarrier by STR analysis of dystrophin gene markers (Fig. 2) . In the other family, although only four microsatellites were informative, a younger sister of the proband did not carry the affected maternal X (Fig. 2) .
Pathological study of EMB. Light microscopy examination of the endomyocardial biopsy samples showed the nonspecific pathologic changes commonly seen in DCM patients (myofibrillar lysis/myocyte damage and interstitial fibrosis). Biopsies from patients with rod domain defects showed severe reduction or absence of immunoreactivity with both rod and midrod domain antibodies; the immunoreactivity for the N-and C-terminus was mildly reduced and focally discontinuous. Dystrophin was almost absent in the biopsies of three patients with unidentified genetic defect and of those with defects affecting N-terminus; a few myocytes retained discontinuous dystrophin expression, particularly with antibodies for C-terminus (Fig. 3) . Dystrophin-associated glycoproteins were irregularly expressed (focal interruptions and reduced immunostain), but in no case was any of the dystrophin associated glycoproteins absent. Patterns of DAG expression differed among patients; the sarcolemmal staining of merosin and spectrin was normal.
At ultrastructural level, membrane defects were seen in nonhypercontracted myocytes in all cases and where characterized by irregular discontinuation of the sarcolemma. In the myocytes with preserved structural integrity, membrane discontinuations were multiple but affected shorter stretches than in severely damaged myocytes, where membrane defects were diffuse and more extensive.
DISCUSSION
Prevalence of dystrophin-related genetic abnormalities in DCM.
Screening a large cohort of consecutive male patients with DCM, we have identified dystrophin gene defects in 6.5%. All patients presented with dominant or 1763 JACC Vol. 35 exclusive cardiac involvement. Nine of 13 had some clinical evidence of mild myopathy, mostly in the form of raised sCPK; two patients had normal sCPK. None developed or showed a progression of skeletal myopathy during followup. We started this program when a heart recipient with pretransplantation diagnosis of idiopathic DCM developed increased sCPK levels one year after surgery. Initially, the increased sCPK was attributed to simvastatin toxicity, but its persistence after simvastatin withdrawal led to reevaluation of the patient. A revised family history documented an X-linked recessive inheritance. The Western blot analysis of a skeletal muscle sample and the molecular analysis of the gene showed a truncated protein and an in-frame deletion spanning exons 45 to 47 (12) . After 1994, we have undertaken a combined immunohistochemical study of EMB samples and molecular DNA screening of most common dystrophin gene defects associated with heart involvement in men presenting with DCM.
Genotype-phenotype correlation. Dystrophin gene deletions spanning exons 45 to 53, recurrently involving exons 46 and 47, have been reported in most DCM associated with dystrophin defects (9, 11, (32) (33) (34) . The integrity of the rod domain (in particular the midrod domain) of the protein plays a major role in structural and functional integrity of the myocyte sarcolemma; intronic segments from this region could include sequences relevant to the function of dystrophin in cardiac muscle (9, 33) . Eight of our patients had deletions exclusively affecting rod domain exons; all were older than 20 and had slowly progressive DCM. None had overt myopathy. Four of the five remaining cases were younger than 20; all had increased sCPK. Two of these patients, in whom the molecular defect has been identified, had multiple and noncontiguous deletions of N-terminal and midrod domain exons. Although rare, these defects may occur (35) . Although all patients presented with dominant cardiac involvement, rod domain exon deletions seem to be associated with normal to moderately increased sCPK and more benign clinical outcome, while earlier defects are associated with a faster evolution and high sCPK levels.
Identification of dystrophin defects in DCM patients.
Light microscopy study of EMB samples does not contribute to the diagnosis. With conventional histopathology, we did not identify any specific morphological marker useful to distinguish dystrophin gene defect-related cardiomyopathy from "idiopathic" DCM. Ultrastructural study raised some suspicion, but the diagnosis cannot rely on this type of study. Immunohistochemical study of the different dystrophin domains plays a diagnostic role and should be routinely performed in all young or adult males to obtain a systematic screening. Given that EMB provides a limited amount of Figure 1 . Graph showing the prevalence of dystrophin defectsassociated dilated cardiomyopathies in the overall series of 201 consecutive male patients, grouped by decades of age. Gray bar ϭ DCM; Black bar ϭ dystrophin defect DCM. DCM ϭ dilated cardiomyopathy. Figure 2 . Microsatellite analysis of families of probands 2 and 13. In the family of proband 2, four microsatellites were informative. In the family of proband 13, six microsatellites were informative. Sisters of both probands were shown to be noncarriers.
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Dystrophin Defects in Dilated Cardiomyopathy tissue, it is helpful to undertake parallel tissue studies with molecular analyses on peripheral blood DNA at least for those disorders with known genetic background, such as X-linked DCM. However, with both multiplex and single exon PCR assays, as well as with direct sequencing of those dystrophin gene regions in which single base mutations causing cardiomyopathy have been detected (4, 5) , deletions in other gene regions or unusual mutations (6 -8) are not investigated. This is likely the case of our three patients in whom gene defects were not identified. Therefore, the entire gene should theoretically be analyzed. This implies heavy and expensive workloads. Among policies of analyzing the entire gene in one patient and screening most frequent mutations in the entire patient population, we adopted the latter approach.
To better target screening, useful clinical or biochemical markers should be identified. Raised sCPK levels may potentially indicate dystrophin abnormalities; however, in our series, two patients had normal total sCPK and four had less than a five-fold increase in sCPK levels, as required by BMD diagnostic criteria. Furthermore, five-fold increased sCPK was also reported in patients with X-linked DCM (3, 4, 6, 8) ; therefore, it does not constitute, by itself, a useful marker to assign patients with DCM and proven dystrophin defect to BMD with mild muscular impairment and dominant cardiomyopathy, rather than to the X-linked DCM subgroup. The distinction only seems to rely on the absence of clinically overt myopathy. However, given that none of the reported patients (3-9) had normal skeletal muscle morphology, the distinction seems to be, in some cases, purely semantic. Moreover, because patients with congestive heart failure may develop a secondary peripheral myopathy (36) , a mild sCPK increase may not be sufficiently informative. Finally, in our experience, a prior clinical diagnosis of LGMD, which should by itself exclude a dystrophin defect and which is only exceptionally associated with heart involvement (37), does not exclude dystrophin defects.
Because, at present, we do not have reliable tools to properly assign EMB material to the different types of investigations, our strategy is to screen all DCM male patients for dystrophin gene defects. However, the information obtained from present research has provided the basis for a more critical approach. We developed and are adopting a better targeted diagnostic protocol for evaluation of male patients with DCM. Given that 14 of the overall 201 patients had raised levels of sCPK with normal sCPK-MB and that 10 of them (71.4%) belong to the group of patients affected by dystrophin defects, we routinely perform molecular screening on peripheral blood DNA, even before EMB, in all patients with increased sCPK levels. The same approach is used for patients with clinical suspicion of BMD and LGMD. If molecular analysis identifies dystrophin defects, EMB or skeletal muscle biopsy is not an obligate diagnostic step. On the other hand, if routine molecular analysis does not identify gene defects, tissue studies are necessary. For men with normal or minimally raised sCPK who are younger than 30, EMB is essential; when dystrophin immunostain is normal, no further molecular analysis is necessary. In cases of abnormal immunostain, gene defects should be investigated. However, a recent finding complicates our approach: enteroviruses, which may be causally linked to DCM, have been shown to synthesize enzymes that are able to cleave dystrophin, thus modifying the integrity of membrane immunostain (38) . More complex is the approach to the screening of patients older than 30 years with normal sCPK levels. The likelihood of finding a dystrophin defect in these patients is, in our experience, very low (2 of 161, 1.2%) but not null, and, in any case, all patients should be given equal chances for diagnosis. Therefore, costs and efforts have to be balanced with beneficial effects deriving from the correct diagnosis. Benefits are for relatives more than for the probands themselves; namely brothers for potential preclinical diagnosis, sisters and maternal aunts as potential carriers and, for older patients, daughters as obliged carriers, given that fertility is not affected by the disease. Immunostaining for dystrophin routine EMB samples is the first screening approach in unsuspected adult patients with normal CPK; molecular analysis will be limited to cases with irregular or unclear immunolabeling results.
In conclusion, routine clinical and laboratory evaluation may not distinguish dystrophin-defect-associated cardiomyopathy from idiopathic DCM. In particular, sCPK levels may be normal or lower than those reported in BMD. Immunohistochemical and molecular studies are essential to identify protein and gene defects. The observed prevalence of dystrophin-related DCM may not represent a real estimate of the disease in the overall group of DCM. In particular, our results may be biased (especially for the relatively high proportion of patients younger than 30 years [17.4%]) by the characteristics of our institution, which is a tertiary academic hospital for chronic heart failure and cardiac transplantation, and by the ethnic origin of the tested population. Screening studies performed in different settings and ethnically distinct populations might give different results. In this regard, further data are needed.
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